Anti-obesity fixed-dose combinations

Gradman AH Basile JN Carter BL Bakris GL . Combination therapy in hypertension. J Am Soc Hypertension 2010;4:42-50.

Sharma M Ansari MT Abou-Setta AM . Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151;622-30.

Bailey CJ Day C : Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33.

Bajaj M DeFronzo RA . Combination therapy in type 2 diabetes. In International Textbook of Diabetes Mellitus, 3rd edition. DeFronzo R Ferrannini E Keen H Zimmet P , editors. Wiley, Chichester, 2008, pp915-950.

Day C . Oral antidiabetic agents: Is it time to combine therapies? Diabetes and Primary Care 2006;8:124-33.

Bailey CJ Kodack M . Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 65:314-22, 2011.

Schernthaner G : Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med 2010;27:739-43.

Bailey CJ . Whence and whither the fixed-dose combination? Diabetes Vasc Dis Res 2005;2:51-53.

Day C Bailey CJ . Pharmacological approaches to reduce adiposity. Br J Diabetes Vasc Dis 2006;6:121-5.

Bailey CJ Day C . New pharmacological approaches to obesity. Obesity in Practice 2005;1:2-5.

Sjostrom L Rissanen A Anderson T . Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.

James WPT Astrup A Finer N . Effect of sibutramine on weight maintenance and weight loss: a randomised trial. Lancet 2000;356:2119-25.

Bray GA . Pharmacological treatment of obesity. In Handbook of Obesity, Bray GA Buchard C James WPT (eds). New York, Marcel Dekker, 1998, pp 953-75.

Lee Z Maglione M Tu W . Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.

Rucker D Padwall R Li SK . Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-1204.

Committee for medicinal products for human use (CHMP) Guideline on clinical evaluation of medicinal products used in weight control-http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003264.pdf (Accessed January 2012).

FDA Guidance for industry. Developing products for weight management. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf (Accessed January 2012).

European withdrawal of anorectic agents/appetite suppressants: new legal developments, not new safety issues: Licences for phentermine and amfepramone being withdrawn May 2001. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019540 . (Accessed January 2012).

Jollis JG Landolfo CK Kisslo J . Fenfluramine and phentermine and cardiovascular findings. Circulation 2000;101:2071-77.

Topal EJ Bouser M-G Fox KAA . Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010;376:517-23.

James WPT Caterson ID Countinho W . Effect of sibutramine on cardiovascular outcomes in overwieght and obese subjects. New Engl J Med 2012;363:905-17.

Bailey CJ Feher MD . Diabetes Therapies: treating hyperglycaemia. MedEd UK, Halesowen, UK. 2009, pp150.

National prescribing centre. EMA to review liver safety of orlistat http://www.npc.nhs.uk/rapidreview/?p=4523. (Accessed January 2012).

Lorcaserin. http://www.tesofensine-information.com/lorcaserin.html (Accessed January 2012).

Lee MW Fukioka K . Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 2009;10:1841-45.

Tesofensine. http://www.tesofensine-information.com (Accessed January 2012).

Wadden TA Foreyt JP Foster GD . Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behaviour modification: the COR-BMID trial. Obesity 2011;19:110-20.

Contrave http://www.tesofensine-information.com/contrave.html (Accessed January 2012).

Empatic. http://www.tesofensine-information.com/empatic.html . (Accessed January 2012).

Qnexa. http://www.tesofensine-information.com/qnexa.html (Accessed January 2012).

Heymsfield SB Greenberg SB Fujioka K . Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75.

Field BCT Wren AM Peters V . PYY_3–36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59:1635-9.